Catalyst Pharmaceuticals, Inc.
CPRX
$23.10
$0.482.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 148.39M | 146.56M | 141.42M | 141.82M | 128.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.39M | 146.56M | 141.42M | 141.82M | 128.70M |
| Cost of Revenue | 25.31M | 24.97M | 21.80M | 25.44M | 22.56M |
| Gross Profit | 123.08M | 121.59M | 119.62M | 116.38M | 106.13M |
| SG&A Expenses | 47.47M | 45.95M | 46.91M | 44.19M | 45.88M |
| Depreciation & Amortization | 9.34M | 9.34M | 9.35M | 9.34M | 9.35M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.13M | 80.27M | 78.05M | 78.98M | 77.79M |
| Operating Income | 66.27M | 66.30M | 63.37M | 62.84M | 50.91M |
| Income Before Tax | 71.04M | 69.29M | 71.29M | 74.18M | 57.21M |
| Income Tax Expenses | 18.25M | 17.19M | 14.55M | 18.25M | 13.32M |
| Earnings from Continuing Operations | 52.78M | 52.11M | 56.74M | 55.94M | 43.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.78M | 52.11M | 56.74M | 55.94M | 43.88M |
| EBIT | 66.27M | 66.30M | 63.37M | 62.84M | 50.91M |
| EBITDA | 75.68M | 75.76M | 72.83M | 72.30M | 60.36M |
| EPS Basic | 0.43 | 0.43 | 0.47 | 0.47 | 0.37 |
| Normalized Basic EPS | 0.37 | 0.37 | 0.35 | 0.35 | 0.29 |
| EPS Diluted | 0.42 | 0.41 | 0.45 | 0.44 | 0.35 |
| Normalized Diluted EPS | 0.36 | 0.35 | 0.34 | 0.33 | 0.28 |
| Average Basic Shares Outstanding | 122.60M | 122.16M | 121.47M | 119.89M | 118.93M |
| Average Diluted Shares Outstanding | 127.09M | 127.54M | 126.96M | 126.28M | 125.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |